摘要
目的观察在玻璃体内注射曲安奈德治疗糖尿病性黄斑水肿的临床效果和安全性。方法选取糖尿病黄斑水肿患者45例进行玻璃体内注射40 mg/mL曲安奈德0.1 mL并在治疗后的1、3个月观察患者的视力、视网膜厚度、眼压的变化和黄斑水肿的改善情况。结果治疗后1个月视力为(0.41±0.19),治疗后3个月视力为(0.45±0.21);治疗后1个月黄斑中心凹的厚度为(295.37±38.73)μm,治疗后3个月,黄斑中心凹的厚度为(296.52±39.46)μm,与治疗前比较差异有统计学意义(P<0.05)。治疗后随访的患者眼压在正常范围,未出现并发症。结论玻璃体内注射曲安奈德对于治疗糖尿病性黄斑水肿有一定的疗效和安全性。
Objective To observe the clinical curative effect and security of intra-vitreous injection of Triamcinolone Acetonide for diabetic macular edema. Methods 45 patients with diabetic macular edema were injected 40 mg/mL Tri- amcinolone Acetonide 0.1 mL in vitreous for treatment. The follow-up duration was 1 month and 3 months. The visual acuity, intraocular pressure and retinal thickness at the macular area were observed and compared before and after treatment. Results 1 month and 3 months after the injection, the mean extent of improvement of visual acuity was （0.41±0.19） and （0.45±0.21）; while the decrease of retinal thickness at macula was （295.37±38.73） μm and （296.52± 39.46）μm. Compared with before treatment, the difference was significant （P 〈 0.05）. Intraocular pressure was in the normal range and complications were not found after treatment. Conclusion Triamcinolone Acetonide is effective and safe for diabetic macular edema.
出处
《中国医药导报》
CAS
2014年第3期73-75,共3页
China Medical Herald
基金
国家自然科学基金项目(编号81070655)
关键词
玻璃体
曲安奈德
糖尿病性黄斑水肿
Vitreous
Triamcinolone Acetonide
Diabetic macular edema
